10.17.24 -- BIOSECURE Act Passes House. How Will It Impact Your Outsourcing?

BioPlan Associates 21st Annual Report found biopharma companies want lower cost single-use system options over any other new product development area.

Binding reagents play a critical role in immunoassays. Learn how reagent selection, generation, and characterization can enhance assay precision, consistency, and reliability.

Medtech OEMs, contract manufacturers, and other partners involved in the device life cycle are increasingly realizing additional benefits by making sustainability a group exercise.

Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.

Gain the knowledge and skills needed to effectively navigate the complex clinical supply distribution landscape within this important and rapidly growing region.

Drug product stability may be seriously compromised if mannitol completes crystallization during storage rather than during the freezing or annealing step in the lyophilization process.

Delve into the key obstacles encountered in biologics process development, including the complexities of optimizing production processes, ensuring product consistency, and maintaining quality control.

Review the evolution and future potential of microbial manufacturing in the biopharmaceutical industry to discover how digital tools can revolutionize development and production processes.

Compare the pros and cons of soluble and insoluble processes, experiences with isolating, solubilizing, and properly re-folding, and strategies and innovation to improve insoluble processes.

Consider the advantages of 2000 and 3000 L single-use mixing systems and experimental results demonstrating their capacity to deliver high power at large scales and flexibility for use at lower volumes.

Uncover how a biopharmaceutical company can de-risk the launch process by choosing a suitable autoinjector technology and partner.

Partner Week is back this October! From 10/21 through 10/25, hear from CDMOs across Fill/Finish, Large Molecule, Small Molecule, Cell & Gene, and our newest addition: ADC. Bring your questions and requirements, skip the small talk, and get right down to the business of finding the best-fit partner for your short- and longer-term drug development needs. Register for free at this link.

Lonza’s Drug Product Services delivers a holistic approach to DP development that prevents problems early and produces a product that is fit for purpose.

See how comprehensive drug product fill and finish services streamline the journey from formulation development to commercialization, ensuring quality, efficiency, and compliance at every stage.

KBI uses an early optimization workflow to ensure manufacturing success. As a result, more molecules are manufactured using an E. Coli expression system than ever before.

This brochure explains how our parallel development service works seamlessly with our existing antibody capabilities, helping to accelerate your ADC program and reach the market faster.

Leveraging the expertise and flexibility of a partner empowers you to ensure regulatory compliance from the outset, with thorough characterization starting at the earliest stages.